
News|Articles|January 1, 2004
Docetaxel/platinum combinations are efficacious in treatment of NSCLC
A regimen of docetaxel and cisplatin offers better survival and response rates than a combination of vinorelbine and cisplatin in the treatment of advanced non-small-cell lung cancer, according to a phase 3 study published in the online version of the Journal of Clinical Oncology. In addition, the findings demonstrated that docetaxel is as effective as vinorelbine/cisplatin when combined with another platinum, carboplatin.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
3
A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk
4
Intervention boosts connected insulin pen adoption among minorities with Type 1 diabetes
5


























